Login / Signup

The fate of biocontrol agents under the European phytopharmaceutical regulation: how this regulation hinders the approval of botanicals as new active substances.

Marie-Cécile VekemansPatrice André Marchand
Published in: Environmental science and pollution research international (2020)
The use of biocontrol agents (BCAs) is growing across the world and in Europe in particular, where novel ways of farming are highly encouraged and implemented. However, although the social pressure is high to increase the number of BCAs in use within the EU, the European plant protection products (PPP) regulation (EC) N° 1107/2009 does not define clearly what BCAs are. Therefore, problems and drawbacks are observed throughout the whole authorisation process. Consequently, this situation impedes drastically the rapid implementation of botanical BCAs and their subsequent use in the field. Previous studies described in detail the fate of BCAs and the current administrative process that leads to their approval. Drawbacks are described for GMOs but surprisingly scarcely for pesticides. Therefore, the present study pinpoints the drawbacks of the approval process of botanical BCAs. To achieve this goal, a comparative study of 5 substances (4 of plant origin and 1 chemical) was performed. This study clearly reveals the present weaknesses and loopholes in the European PPP regulation process. The results of the present study may be useful to initiate and promote a major change in the evaluation and the regulation process of BCAs. This should allow designing a novel and innovative framework enabling the development of future plant protection products according to the sustainable use of pesticides, described in the corresponding (EC) Directive N° 128/2009 (SUD). This work targets farmers, policy makers, NGOs and scientists interested in issues related to this topic.
Keyphrases
  • healthcare
  • risk assessment
  • public health
  • primary care
  • quality improvement
  • quantum dots
  • drug induced